Implementing Programmatic Changes Required for New Cellular Therapy Quality Standards and Data Registry Reporting

Background: Although viewed today as novel, the use of chimeric antigen receptor (CAR) T-cell therapy is on the verge of becoming a conventional treatment. Two years ago, the Center for International Blood and Marrow Transplant Research (CIBMTR) issued a request for voluntary reporting of non-hematopoietic cell transplantation (non-HCT) related cellular therapies. Subsequently, the Foundation for the Accreditation of Cellular Therapy (FACT) released new standards requiring programs to implement quality metrics associated with cellular therapy (i.e., immune effector cells).

Source: Biology of Blood and Marrow Transplantation - February 1, 2018 Category: Hematology Authors: Claudette G. Edwards, Laurian Walters, Lazaros J. Lekakis, Nathalie Luis, Cara L. Benjamin, Debra Chinquee, Patricia Gomez, Krishna V. Komanduri Source Type: research